tandutinib

DRUG4 trials

Sponsors

Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI)

Conditions

Acute Myelogenous LeukemiaAdult Brain TumorAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaClear Cell Renal Cell CarcinomaMetastatic CancerPain

Phase 1

A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy

WithdrawnNCT00297921

Millennium Pharmaceuticals, Inc.Acute Myelogenous Leukemia

Updated: 2013-11-06

Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma

CompletedNCT00379080

National Cancer Institute (NCI)Adult Brain Tumor, Adult Giant Cell Glioblastoma, Adult Glioblastoma +2

Start: 2007-01-31End: 2013-06-30Updated: 2017-04-07

Phase 2

Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases

CompletedNCT00390468

National Cancer Institute (NCI)Metastatic Cancer, Pain, Prostate Cancer

Start: 2006-10-31End: 2009-11-30Updated: 2014-05-28

Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer

CompletedNCT00408902

National Cancer Institute (NCI)Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer

Start: 2006-11-30End: 2008-12-31Updated: 2017-11-22